GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Cooper Companies Inc (STU:CP60) » Definitions » Capex-to-Revenue

The Cooper (STU:CP60) Capex-to-Revenue : 0.08 (As of Apr. 2024)


View and export this data going back to 1983. Start your Free Trial

What is The Cooper Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

The Cooper's Capital Expenditure for the three months ended in Apr. 2024 was €-69.06 Mil. Its Revenue for the three months ended in Apr. 2024 was €878.50 Mil.

Hence, The Cooper's Capex-to-Revenue for the three months ended in Apr. 2024 was 0.08.


The Cooper Capex-to-Revenue Historical Data

The historical data trend for The Cooper's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Cooper Capex-to-Revenue Chart

The Cooper Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.13 0.07 0.07 0.11

The Cooper Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.10 0.16 0.13 0.08

Competitive Comparison of The Cooper's Capex-to-Revenue

For the Medical Instruments & Supplies subindustry, The Cooper's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Cooper's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where The Cooper's Capex-to-Revenue falls into.



The Cooper Capex-to-Revenue Calculation

The Cooper's Capex-to-Revenue for the fiscal year that ended in Oct. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-371.697) / 3402.76
=0.11

The Cooper's Capex-to-Revenue for the quarter that ended in Apr. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-69.061) / 878.503
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


The Cooper  (STU:CP60) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


The Cooper Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of The Cooper's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


The Cooper (STU:CP60) Business Description

Traded in Other Exchanges
Address
6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583
The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.

The Cooper (STU:CP60) Headlines

No Headlines